Literature DB >> 21453126

Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice.

Taeyoung Koo1, Alberto Malerba, Takis Athanasopoulos, Capucine Trollet, Luisa Boldrin, Arnaud Ferry, Linda Popplewell, Helen Foster, Keith Foster, George Dickson.   

Abstract

Duchenne muscular dystrophy is a severe X-linked inherited muscle wasting disorder caused by mutations in the dystrophin gene. Adeno-associated virus (AAV) vectors have been extensively used to deliver genes efficiently for dystrophin expression in skeletal muscles. To overcome limited packaging capacity of AAV vectors (<5 kb), truncated recombinant microdystrophin genes with deletions of most of rod and carboxyl-terminal (CT) domains of dystrophin have been developed. We have previously shown the efficiency of mRNA sequence-optimized microdystrophin (ΔR4-23/ΔCT, called MD1) with deletion of spectrin-like repeat domain 4 to 23 and CT domain in ameliorating the pathology of dystrophic mdx mice. However, the CT domain of dystrophin is thought to recruit part of the dystrophin-associated protein complex, which acts as a mediator of signaling between extracellular matrix and cytoskeleton in muscle fibers. In this study, we extended the ΔR4-23/ΔCT microdystrophin by incorporating helix 1 of the coiled-coil motif in the CT domain of dystrophin (MD2), which contains the α1-syntrophin and α-dystrobrevin binding sites. Intramuscular injection of AAV2/9 expressing CT domain-extended microdystrophin showed efficient dystrophin expression in tibialis anterior muscles of mdx mice. The presence of the CT domain of dystrophin in MD2 increased the recruitment of α1-syntrophin and α-dystrobrevin at the sarcolemma and significantly improved the muscle resistance to lengthening contraction-induced muscle damage in the mdx mice compared with MD1. These results suggest that the incorporation of helix 1 of the coiled-coil motif in the CT domain of dystrophin to the microdystrophins will substantially improve their efficiency in restoring muscle function in patients with Duchenne muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21453126      PMCID: PMC3225045          DOI: 10.1089/hum.2011.020

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  35 in total

1.  Hybrid adeno-associated virus bearing nonhomologous inverted terminal repeats enhances dual-vector reconstruction of minigenes in vivo.

Authors:  Ziying Yan; Diana C M Lei-Butters; Yulong Zhang; Roman Zak; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2007-01       Impact factor: 5.695

2.  Characterization of a novel Dp71 dystrophin-associated protein complex (DAPC) present in the nucleus of HeLa cells: members of the nuclear DAPC associate with the nuclear matrix.

Authors:  Lizeth Fuentes-Mera; Rafael Rodríguez-Muñoz; Ricardo González-Ramírez; Francisco García-Sierra; Everardo González; Dominique Mornet; Bulmaro Cisneros
Journal:  Exp Cell Res       Date:  2006-06-07       Impact factor: 3.905

3.  C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout mice.

Authors:  Yongping Yue; Mingju Liu; Dongsheng Duan
Journal:  Mol Ther       Date:  2006-03-23       Impact factor: 11.454

Review 4.  Increasing complexity of the dystrophin-associated protein complex.

Authors:  J M Tinsley; D J Blake; R A Zuellig; K E Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

5.  AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype.

Authors:  Madoka Yoshimura; Miki Sakamoto; Madoka Ikemoto; Yasushi Mochizuki; Katsutoshi Yuasa; Yuko Miyagoe-Suzuki; Shin'ichi Takeda
Journal:  Mol Ther       Date:  2004-11       Impact factor: 11.454

6.  Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.

Authors:  M Koenig; E P Hoffman; C J Bertelson; A P Monaco; C Feener; L M Kunkel
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

7.  Evolutionary conservation of the dystrophin central rod domain.

Authors:  T G Sherratt; T Vulliamy; P N Strong
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

8.  Dystrophin protects the sarcolemma from stresses developed during muscle contraction.

Authors:  B J Petrof; J B Shrager; H H Stedman; A M Kelly; H L Sweeney
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

9.  Mammalian alpha 1- and beta 1-syntrophin bind to the alternative splice-prone region of the dystrophin COOH terminus.

Authors:  A Suzuki; M Yoshida; E Ozawa
Journal:  J Cell Biol       Date:  1995-02       Impact factor: 10.539

10.  Syntrophin binds to an alternatively spliced exon of dystrophin.

Authors:  A H Ahn; L M Kunkel
Journal:  J Cell Biol       Date:  1995-02       Impact factor: 10.539

View more
  25 in total

1.  Dystrobrevin increases dystrophin's binding to the dystrophin-glycoprotein complex and provides protection during cardiac stress.

Authors:  Jana Strakova; Jon D Dean; Katharine M Sharpe; Tatyana A Meyers; Guy L Odom; DeWayne Townsend
Journal:  J Mol Cell Cardiol       Date:  2014-08-24       Impact factor: 5.000

Review 2.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

3.  Multiple recombinant adeno-associated viral vector serotypes display persistent in vivo gene expression in vector-transduced rat stifle joints.

Authors:  Jeffrey B Mason; Brittney L Gurda; Julie B Engiles; Kurt D Hankenson; James M Wilson; Dean W Richardson
Journal:  Hum Gene Ther Methods       Date:  2013-06       Impact factor: 2.396

4.  Long-term episomal transgene expression from mitotically stable integration-deficient lentiviral vectors.

Authors:  Hanna Kymäläinen; J Uwe Appelt; Frank A Giordano; Angela F Davies; Caroline M Ogilvie; Sherif G Ahmed; Stephanie Laufs; Manfred Schmidt; Juergen Bode; Rafael J Yáñez-Muñoz; George Dickson
Journal:  Hum Gene Ther       Date:  2014-04-10       Impact factor: 5.695

5.  Conserved regions of the DMD 3' UTR regulate translation and mRNA abundance in cultured myotubes.

Authors:  C Aaron Larsen; Michael T Howard
Journal:  Neuromuscul Disord       Date:  2014-05-22       Impact factor: 4.296

6.  Single Intramuscular Injection of AAV-shRNA Reduces DNM2 and Prevents Myotubular Myopathy in Mice.

Authors:  Hichem Tasfaout; Valentina M Lionello; Christine Kretz; Pascale Koebel; Nadia Messaddeq; Deborah Bitz; Jocelyn Laporte; Belinda S Cowling
Journal:  Mol Ther       Date:  2018-02-14       Impact factor: 11.454

7.  Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model.

Authors:  Kasun Kodippili; Chady H Hakim; Xiufang Pan; Hsiao T Yang; Yongping Yue; Yadong Zhang; Jin-Hong Shin; N Nora Yang; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2017-08-04       Impact factor: 5.695

8.  Full-length dystrophin reconstitution with adeno-associated viral vectors.

Authors:  William Lostal; Kasun Kodippili; Yongping Yue; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2014-03-31       Impact factor: 5.695

9.  Phosphorylation within the cysteine-rich region of dystrophin enhances its association with β-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting.

Authors:  Kristy Swiderski; Scott A Shaffer; Byron Gallis; Guy L Odom; Andrea L Arnett; J Scott Edgar; Dale M Baum; Annabel Chee; Timur Naim; Paul Gregorevic; Kate T Murphy; James Moody; David R Goodlett; Gordon S Lynch; Jeffrey S Chamberlain
Journal:  Hum Mol Genet       Date:  2014-07-31       Impact factor: 6.150

10.  The Rag2⁻Il2rb⁻Dmd⁻ mouse: a novel dystrophic and immunodeficient model to assess innovating therapeutic strategies for muscular dystrophies.

Authors:  Denis Vallese; Elisa Negroni; Stéphanie Duguez; Arnaud Ferry; Capucine Trollet; Ahmed Aamiri; Christian A J Vosshenrich; Ernst-Martin Füchtbauer; James P Di Santo; Libero Vitiello; Gillian Butler-Browne; Vincent Mouly
Journal:  Mol Ther       Date:  2013-08-23       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.